argenx SE (NAS:ARGX)
$ 356.01 -3.47 (-0.97%) Market Cap: 21.22 Bil Enterprise Value: 18.74 Bil PE Ratio: 0 PB Ratio: 5.39 GF Score: 74/100

argenx SE at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 12:30PM GMT
Release Date Price: $301.66 (-3.49%)
James Daniel Gordon
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, and good afternoon. I'm James Gordon, JPMorgan European farmland biotech analyst. And today, kicking off the JPMorgan Healthcare Conference from the European side, I have the pleasure of introducing the argenx presentation and Q&A. So argenx CEO, Tim Van Hauwermeiren joining us, and it's an exciting time to talk to the company following FDA approval of Vyvgart for MG late last year. So really looking forward to the presentation. Thanks a lot. Over to you, Tim.

Timothy Van Hauwermeiren
argenx SE - CEO & Executive Director

Thank you, James, and good morning and good afternoon, ladies and gentlemen. A very warm welcome to this argenx presentation. During the next 20 minutes, I will share our excitement about the year 2022, which is going to be an incredible year for us. We will see a great cadence of commercial Vyvgart launches. We will see numerous clinical catalysts and we will show how we continue to build a world-class product pipeline. We will discuss how

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot